These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11074529)

  • 1. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia.
    Vacherot F; Azzouz M; Gil-Diez-De-Medina S; Colombel M; De La Taille A; Lefrère Belda MA; Abbou CC; Raynaud JP; Chopin DK
    Prostate; 2000 Nov; 45(3):259-66. PubMed ID: 11074529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
    Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
    Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.
    Paubert-Braquet M; Cousse H; Raynaud JP; Mencia-Huerta JM; Braquet P
    Eur Urol; 1998; 33(3):340-7. PubMed ID: 9555564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization.
    Petrangeli E; Lenti L; Buchetti B; Chinzari P; Sale P; Salvatori L; Ravenna L; Lococo E; Morgante E; Russo A; Frati L; Di Silverio F; Russo MA
    J Cell Physiol; 2009 Apr; 219(1):69-76. PubMed ID: 19067321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
    Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.
    Bernichtein S; Pigat N; Camparo P; Latil A; Viltard M; Friedlander G; Goffin V
    Prostate; 2015 May; 75(7):706-22. PubMed ID: 25683150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of permixon on human prostate cell growth: lack of apoptotic action.
    Hill B; Kyprianou N
    Prostate; 2004 Sep; 61(1):73-80. PubMed ID: 15287095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
    Plosker GL; Brogden RN
    Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
    Buck AC
    J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat.
    Paubert-Braquet M; Richardson FO; Servent-Saez N; Gordon WC; Monge MC; Bazan NG; Authie D; Braquet P
    Pharmacol Res; 1996; 34(3-4):171-9. PubMed ID: 9051712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
    Bayne CW; Donnelly F; Ross M; Habib FK
    Prostate; 1999 Sep; 40(4):232-41. PubMed ID: 10420151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
    Latil A; Libon C; Templier M; Junquero D; Lantoine-Adam F; Nguyen T
    BJU Int; 2012 Sep; 110(6 Pt B):E301-7. PubMed ID: 22520557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
    Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
    Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
    Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.
    Sirab N; Robert G; Fasolo V; Descazeaud A; Vacherot F; de la Taille A; Terry S
    Int J Mol Sci; 2013 Jul; 14(7):14301-20. PubMed ID: 23846725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.
    Vela Navarrete R; Garcia Cardoso JV; Barat A; Manzarbeitia F; López Farré A
    Eur Urol; 2003 Nov; 44(5):549-55. PubMed ID: 14572753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
    Zlotta AR; Teillac P; Raynaud JP; Schulman CC
    Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gerber GS; Fitzpatrick JM
    BJU Int; 2004 Aug; 94(3):338-44. PubMed ID: 15291864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate.
    Bayne CW; Ross M; Donnelly F; Habib FK
    J Urol; 2000 Sep; 164(3 Pt 1):876-81. PubMed ID: 10953171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.